Voy­ager's shares sink af­ter ex­ecs say FDA has re­versed course on an ac­cel­er­at­ed fil­ing for its gene ther­a­py

The FDA ap­pears to have lost its ap­petite for an ac­cel­er­at­ed mar­ket­ing ap­pli­ca­tion that could pave the way to an ear­ly OK for Voy­ager’s lead …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.